By Lucy Piper, medwireNews Reporter
medwireNews: Lorundrostat, a selective aldosterone synthase inhibitor, shows blood pressure-lowering potential in people with uncontrolled and treatment-resistant hypertension, according to the Advance-HTN trial.
This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.
Read the full story on the L’Institut Servier website
Image credit: © Kurhan / stock.adobe.com
